THERESA FUKUDA: Open Payments
NPI 1366006330 · BOSTON, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,998 in 155 payments from 18 companies in 2025. Trend: 2023 $2,706 · 2024 $2,034 · 2025 $2,998
Food & beverage: $2,801Education: $197
| Company | Payments | Amount |
|---|---|---|
| UCB, Inc. | 26 | $439 |
| Janssen Biotech, Inc. | 13 | $380 |
| ABBVIE INC. | 27 | $313 |
| Galderma Laboratories, L.P. | 17 | $261 |
| Arcutis Biotherapeutics, Inc. | 15 | $210 |
| Regeneron Healthcare Solutions, Inc. | 8 | $194 |
| Incyte Corporation | 11 | $186 |
| LEO Pharma Inc. | 4 | $177 |
| GENZYME CORPORATION | 8 | $156 |
| Organon LLC | 6 | $121 |
Products named: DUPIXENT, Bimzelx, TREMFYA, SKYRIZI, NEMLUVIO, Zoryve, OPZELURA, ANZUPGO.
Industry payments across MA — which companies pay providers there.
